Skip to content
ModernDoc
Get the app
Condition research / Explore another topicSaved preview · Not clinically reviewed
Myeloma.

The long view. The new questions.
A clearer understanding.

Study reading

Elotuzumab regimens showed mixed side-effect risks

A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.

Evidence period: 2026 Dec2 min readAI-written · Not clinically reviewed

Saved revision 1 · · Revision history

A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences.

What the study found

A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. Source ↗

Elotuzumab-containing regimens had higher pneumonia risk, with a relative risk of 1.30 and a 95% confidence interval of 1.07-1.59, while neutropenia was less frequent. Source ↗

Who and what was studied

People with multiple myeloma enrolled in 6 randomized controlled trials, totaling 1,736 participants. Source ↗

Elotuzumab-containing regimens were compared with control therapies. Source ↗

What remains uncertain

The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased. Source ↗

Follow the evidence.

Source links and automated passage checks do not establish clinical review.

Supporting passages: Elotuzumab regimens showed mixed side-effect risks

6 RCTs (N=1,736) were included. Elotuzumabsignificantly reduced incidence of neutropenia (RR = 0.86, 95% CI: 0.76-0.98), but increased risks of cough (RR = 1.41, 95% CI: 0.96-2.09), pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15). No significant differences were observed for anemia, thrombocytopenia, respiratory infections, nausea, appetite loss, back pain, muscle spasms, peripheral edema, insomnia, rash, pruritus, fatigue, or hypokalemia. For grade 3-4 events, elotuzumab was associated with higher risks of lymphopenia (RR = 1.86, 95% CI: 1.31-2.64, p = 0.0005, I2 = 9%), diarrhea (RR = 1.47, 95% CI: 1.00-2.17), pneumonia (RR = 1.57, 95% CI: 1.11-2.23), cataracts (RR = 2.87, 95% CI: 1.15-7.21) and infections (RR = 1.30, 95% CI: 1.04-1.62).

PMID 41820200 · abstract-3
Supporting passages: A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.

We systematically searched PubMed, Web of Science, EMBASE and CENTRAL through February 13, 2025 for randomized controlled trials (RCTs) evaluating elotuzumab in MM. Pooled relative risks(RRs) of adverse events observed in elotuzumab-containing regimens versus control therapies.

PMID 41820200 · abstract-2

6 RCTs (N=1,736) were included. Elotuzumabsignificantly reduced incidence of neutropenia (RR = 0.86, 95% CI: 0.76-0.98), but increased risks of cough (RR = 1.41, 95% CI: 0.96-2.09), pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15). No significant differences were observed for anemia, thrombocytopenia, respiratory infections, nausea, appetite loss, back pain, muscle spasms, peripheral edema, insomnia, rash, pruritus, fatigue, or hypokalemia. For grade 3-4 events, elotuzumab was associated with higher risks of lymphopenia (RR = 1.86, 95% CI: 1.31-2.64, p = 0.0005, I2 = 9%), diarrhea (RR = 1.47, 95% CI: 1.00-2.17), pneumonia (RR = 1.57, 95% CI: 1.11-2.23), cataracts (RR = 2.87, 95% CI: 1.15-7.21) and infections (RR = 1.30, 95% CI: 1.04-1.62).

PMID 41820200 · abstract-3

Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.

PMID 41820200 · abstract-4
Supporting passages: A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences.

We systematically searched PubMed, Web of Science, EMBASE and CENTRAL through February 13, 2025 for randomized controlled trials (RCTs) evaluating elotuzumab in MM. Pooled relative risks(RRs) of adverse events observed in elotuzumab-containing regimens versus control therapies.

PMID 41820200 · abstract-2

6 RCTs (N=1,736) were included. Elotuzumabsignificantly reduced incidence of neutropenia (RR = 0.86, 95% CI: 0.76-0.98), but increased risks of cough (RR = 1.41, 95% CI: 0.96-2.09), pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15). No significant differences were observed for anemia, thrombocytopenia, respiratory infections, nausea, appetite loss, back pain, muscle spasms, peripheral edema, insomnia, rash, pruritus, fatigue, or hypokalemia. For grade 3-4 events, elotuzumab was associated with higher risks of lymphopenia (RR = 1.86, 95% CI: 1.31-2.64, p = 0.0005, I2 = 9%), diarrhea (RR = 1.47, 95% CI: 1.00-2.17), pneumonia (RR = 1.57, 95% CI: 1.11-2.23), cataracts (RR = 2.87, 95% CI: 1.15-7.21) and infections (RR = 1.30, 95% CI: 1.04-1.62).

PMID 41820200 · abstract-3

Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.

PMID 41820200 · abstract-4
Supporting passages: A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences.

We systematically searched PubMed, Web of Science, EMBASE and CENTRAL through February 13, 2025 for randomized controlled trials (RCTs) evaluating elotuzumab in MM. Pooled relative risks(RRs) of adverse events observed in elotuzumab-containing regimens versus control therapies.

PMID 41820200 · abstract-2

6 RCTs (N=1,736) were included. Elotuzumabsignificantly reduced incidence of neutropenia (RR = 0.86, 95% CI: 0.76-0.98), but increased risks of cough (RR = 1.41, 95% CI: 0.96-2.09), pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15). No significant differences were observed for anemia, thrombocytopenia, respiratory infections, nausea, appetite loss, back pain, muscle spasms, peripheral edema, insomnia, rash, pruritus, fatigue, or hypokalemia. For grade 3-4 events, elotuzumab was associated with higher risks of lymphopenia (RR = 1.86, 95% CI: 1.31-2.64, p = 0.0005, I2 = 9%), diarrhea (RR = 1.47, 95% CI: 1.00-2.17), pneumonia (RR = 1.57, 95% CI: 1.11-2.23), cataracts (RR = 2.87, 95% CI: 1.15-7.21) and infections (RR = 1.30, 95% CI: 1.04-1.62).

PMID 41820200 · abstract-3

Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.

PMID 41820200 · abstract-4
Supporting passages: Elotuzumab-containing regimens had higher pneumonia risk, with a relative risk of 1.30 and a 95% confidence interval of 1.07-1.59, while neutropenia was less frequent.

Elotuzumabsignificantly reduced incidence of neutropenia (RR = 0.86, 95% CI: 0.76-0.98), but increased risks of cough (RR = 1.41, 95% CI: 0.96-2.09), pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15).

PMID 41820200 · abstract-3
Supporting passages: People with multiple myeloma enrolled in 6 randomized controlled trials, totaling 1,736 participants.

We systematically searched PubMed, Web of Science, EMBASE and CENTRAL through February 13, 2025 for randomized controlled trials (RCTs) evaluating elotuzumab in MM.

PMID 41820200 · abstract-2

6 RCTs (N=1,736) were included.

PMID 41820200 · abstract-3
Supporting passages: Elotuzumab-containing regimens were compared with control therapies.

Pooled relative risks(RRs) of adverse events observed in elotuzumab-containing regimens versus control therapies.

PMID 41820200 · abstract-2
Supporting passages: The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.

Pooled relative risks(RRs) of adverse events observed in elotuzumab-containing regimens versus control therapies.

PMID 41820200 · abstract-2

6 RCTs (N=1,736) were included. Elotuzumabsignificantly reduced incidence of neutropenia (RR = 0.86, 95% CI: 0.76-0.98), but increased risks of cough (RR = 1.41, 95% CI: 0.96-2.09), pneumonia (RR = 1.30, 95% CI: 1.07-1.59), diarrhea (RR = 1.16, 95% CI: 1.05-1.30), pyrexia (RR = 1.47, 95% CI: 1.10-1.96) and infections (RR = 1.09, 95% CI: 1.03-1.15). No significant differences were observed for anemia, thrombocytopenia, respiratory infections, nausea, appetite loss, back pain, muscle spasms, peripheral edema, insomnia, rash, pruritus, fatigue, or hypokalemia. For grade 3-4 events, elotuzumab was associated with higher risks of lymphopenia (RR = 1.86, 95% CI: 1.31-2.64, p = 0.0005, I2 = 9%), diarrhea (RR = 1.47, 95% CI: 1.00-2.17), pneumonia (RR = 1.57, 95% CI: 1.11-2.23), cataracts (RR = 2.87, 95% CI: 1.15-7.21) and infections (RR = 1.30, 95% CI: 1.04-1.62).

PMID 41820200 · abstract-3

Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.

PMID 41820200 · abstract-4
  1. Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis. ↗

    2026 Dec

    Source checked: 2026-09-15

There’s more to the story.

Study readings

Daratumumab combination produced more deep treatment responses

Patients with newly diagnosed multiple myeloma who were not having an initial transplant received a combination including daratumumab or the comparison combination without it. More patients receiving daratumumab reached complete response or better and tested negative for minimal residual disease. These responses were more often sustained, while progression-free survival among patients testing negative showed only a nonsignificant trend favoring daratumumab. The trial enrolled patients who were transplant-ineligible or deferred transplant as initial therapy, so it does not establish the same result for all newly diagnosed patients. Among patients who achieved minimal-residual-disease negativity, the progression-free-survival difference was not statistically significant, so an advantage in that subgroup remains uncertain. The median follow-up was 58.7 months, so outcomes beyond that period are not established.

2 min read · 2026 Aug 25

Study readings

Continuing zoledronic acid reduced bone disease progression

In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.

2 min read · 2026 Sep

A publication for curiosity.

AI-written. Not clinically reviewed. Selected sources, not a complete review. No personal treatment matching.

Article revisions preserve earlier writing. Article dates and source-check dates describe different events. Email updates and automatic research refresh are unavailable during this pilot.